Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Epidemiology of Post-Transplant Lymphoproliferative Disorders in Children with Solid Organ Transplant over 34 Years of a Single Center Experience

Marta Rojas Vasquez, MD FRCPC, Anthea Peters, MSc, MD FRCPC, Raymond Lai, MD PhD FRCP, Curtis Mabilangan, MSc, Burton Catherine, MD FRCPC, Jutta Preiksaitis, MDFRCPC

Blood (2019) 134 (Supplement_1): 1602.

https://doi.org/10.1182/blood-2019-125344

Published: 2019

Journal Articles

The Identification of Novel Epigenetic Therapies for ALK-Driven Haematological Malignancies

Stephen P. Ducray, BSc, Ricky Trigg, PhD, Andrew J. Bannister, PhD, Raymond Lai, MD PhD FRCP, Gerda Egger, PhD, Olaf Merkel, PhD, Lukas Kenner, MD, Suzanne Turner, PhD

Blood (2019) 134 (Supplement_1): 1483.

https://doi.org/10.1182/blood-2019-125648

Published: 2019

Journal Articles

CD3 T-Cell Infiltrates at Diagnosis Predicts Overall Survival in Solid Organ Transplant Recipients with Post-Transplant Lymphoproliferative Disorders (PTLD)

Ryan J. Stubbins, MD BSc, James Zhu, BSc, MD, Raymond Lai, MD PhD, Carolyn J. Owen, MD MDes(UK), FRCPC, Jutta Preiksaitis, MD FRCPC, Anthea C Peters, MD M.Sc., FRCPC

Blood (2016) 128 (22): 1873.

https://doi.org/10.1182/blood.V128.22.1873.1873

Published: 2016

Journal Articles

Morphologic Evolution in Post-Transplant Lymphoproliferative Disorders (PTLD): A Clinicopathologic Case Series

Ryan J. Stubbins, MD BSc, Anthea C Peters, MD M.Sc., FRCPC, Mabilang Curtis, BSc, Carolyn Owen, MD, Adnan Mansoor, MD FRCPC, Raymond Lai, MD PhD, Jutta Preiksaitis, MD FRCPC

Blood (2015) 126 (23): 5008.

https://doi.org/10.1182/blood.V126.23.5008.5008

Published: 2015

Journal Articles

High Oct-2 Protein Expression Is Associated with Decreased Overall Survival, While High Bob-1 Protein Expression Is Associated with Improved Overall Survival in Myeloma Patients.

Inka Toman, M.Sc., Jonathan Loree, Alex Klimowicz, Ph.D., Nizar J Bahlis, MD, Raymond Lai, MD, PhD, Andrew Belch, MD, Linda M. Pilarski, PhD, Tony Reiman, MD

Blood (2009) 114 (22): 2822.

https://doi.org/10.1182/blood.V114.22.2822.2822

Published: 2009

Journal Articles

Southwest Oncology Group Study S0530: A Phase 2 Trial of Clofarabine/ Cytarabine for Relapsed/ Refractory Acute Lymphocytic Leukemia.

Anjali Advani, MD, Holly Gundacker, MS, Olga Sala-Torra, MD, Jerald Radich, MD, Raymond Lai, MD, PhD, Marilyn L. Slovak, PhD, Jeffrey E Lancet, MD, Steve Coutre, MD, Robert K Stuart, MD, Martha P. Mims, MD, PhD, Patrick Stiff, MD, Frederick R. Appelbaum, MD

Blood (2009) 114 (22): 3094.

https://doi.org/10.1182/blood.V114.22.3094.3094

Published: 2009

Journal Articles

Epigenetic Regulation of the WNT Canonical Pathway in Mantle Cell Lymphoma.

Anthea C Peters, MD, MSc, Randy Chung, MD, Charles S Wong, Leah C Young, PhD, Tony Reiman, MD, Raymond Lai, MD, PhD

Blood (2008) 112 (11): 3340.

https://doi.org/10.1182/blood.V112.11.3340.3340

Published: 2008

Journal Articles

Determining the Mechanism of Transformation of Follicular Lymphoma into Diffuse Large B Cell Lymphoma.

Emanuela Carlotti, PhD, David Wrench, MD, Sameena Iqbal, BSc, Derville O’Shea, MD, Andrew Davies, MD, PhD, Priya Virappane, BSc, Jason Hart, MD, Raymond Lai, MD, PhD, John G. Gribben, MD, DSc, Andrew T. Lister, MD, Jude Fitzgibbon, PhD

Blood (2007) 110 (11): 181.

https://doi.org/10.1182/blood.V110.11.181.181

Published: 2007

Journal Articles

Bortezomib Activity Against Mantle Cell Lymphoma Overcomes Classic Mechanisms of Drug Resistance and Targets Cell Cycle Control.

Edgar G. Rizzatti, MD, PhD, Helena Mora-Jensen, BS, Elinor Lee, BS, Yuji Miura, MD/PhD, Raymond Lai, MD/PhD, Masanori Daibata, MD, Adrian Wiestner, MD/PhD

Blood (2006) 108 (11): 4393.

https://doi.org/10.1182/blood.V108.11.4393.4393

Published: 2006

Journal Articles

Bortezomib Induces an Antioxidant and ER-Stress Response Gene Expression Signature in Mantle Cell Lymphoma: Implications for Response Prediction and Optimized Chemotherapy Regimens.

Edgar G. Rizzatti, MD, PhD, Helena Mora-Jensen, BS, Raymond Lai, MD/PhD, Masanori Daibata, MD, Therese White, RN, Kieron Dunleavy, MD, Wyndham Wilson, MD/PhD, Adrian Wiestner, MD/PhD

Blood (2006) 108 (11): 830.

https://doi.org/10.1182/blood.V108.11.830.830

Published: 2006

Journal Articles

Role of Jak3 in Chronic Myeloid Leukemia: Evidence To Identify Jak3 as a Potential Therapeutic Target.

Quan Lin, MD, MS, M. Ludmila Prudkin, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Esther Lau, Ioannis Grammatikakis, Vilmos A. Thomazy, MD, PhD, Raymond Lai, MD, PhD, Hesham M. Amin, MD, MSc

Blood (2005) 106 (11): 2870.

https://doi.org/10.1182/blood.V106.11.2870.2870

Published: 2005

Journal Articles

Gene Expression Analysis Uncovers Possible Resistance Mechanisms to Bortezomib in Mantle Cell Lymphoma That Differ from Mechanisms Identified in Other Lymphoid Malignancies.

Edgar G. Rizzatti, MD, PhD, Helena I. Mora-Jensen, Eric Billings, PhD, Raymond Lai, MD, PhD, Adrian Wiestner, MD, PhD

Blood (2005) 106 (11): 2412.

https://doi.org/10.1182/blood.V106.11.2412.2412

Published: 2005

NARROW

Epidemiology of Post-Transplant Lymphoproliferative Disorders in Children with Solid Organ Transplant over 34 Years of a Single Center Experience

The Identification of Novel Epigenetic Therapies for ALK-Driven Haematological Malignancies

CD3 T-Cell Infiltrates at Diagnosis Predicts Overall Survival in Solid Organ Transplant Recipients with Post-Transplant Lymphoproliferative Disorders (PTLD)

Morphologic Evolution in Post-Transplant Lymphoproliferative Disorders (PTLD): A Clinicopathologic Case Series

High Oct-2 Protein Expression Is Associated with Decreased Overall Survival, While High Bob-1 Protein Expression Is Associated with Improved Overall Survival in Myeloma Patients.

Southwest Oncology Group Study S0530: A Phase 2 Trial of Clofarabine/ Cytarabine for Relapsed/ Refractory Acute Lymphocytic Leukemia.

Epigenetic Regulation of the WNT Canonical Pathway in Mantle Cell Lymphoma.

Determining the Mechanism of Transformation of Follicular Lymphoma into Diffuse Large B Cell Lymphoma.

Bortezomib Activity Against Mantle Cell Lymphoma Overcomes Classic Mechanisms of Drug Resistance and Targets Cell Cycle Control.

Bortezomib Induces an Antioxidant and ER-Stress Response Gene Expression Signature in Mantle Cell Lymphoma: Implications for Response Prediction and Optimized Chemotherapy Regimens.

Role of Jak3 in Chronic Myeloid Leukemia: Evidence To Identify Jak3 as a Potential Therapeutic Target.

Gene Expression Analysis Uncovers Possible Resistance Mechanisms to Bortezomib in Mantle Cell Lymphoma That Differ from Mechanisms Identified in Other Lymphoid Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only